Lantheus Holdings, Inc. is a leading radiopharmaceutical-focused company dedicated to delivering life-changing science to enable clinicians to "Find, Fight and Follow" disease, ultimately improving patient outcomes. The company specializes in developing and marketing products that assist healthcare professionals in detecting, treating, and monitoring diseases, with a strong focus on oncology and cardiology. Lantheus sells its products primarily in the United States and also distributes internationally through direct and third-party channels.
- Radiopharmaceutical Oncology - Develops and markets products for detecting, treating, and monitoring cancer, with a focus on prostate cancer. Key products include PYLARIFY, a leading diagnostic agent in this category .
- Precision Diagnostics - Provides diagnostic information to help healthcare professionals detect and characterize diseases, primarily in cardiology. Notable products include DEFINITY, an ultrasound enhancing agent, and other nuclear imaging products like TechneLite and Xenon .
- Strategic Partnerships and Other Revenue - Engages in out-licensing arrangements and partnerships to enable precision medicine through biomarkers, digital solutions, and radiotherapeutic platforms. This includes products like MK-6240 and NAV-4694 for Alzheimer's disease imaging .
You might also like
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Brian Markison ExecutiveBoard | Chief Executive Officer (CEO) | Director of RVL Pharmaceuticals plc, Cosette Pharmaceuticals, and The College of New Jersey. | Over 40 years of pharmaceutical industry experience; previously Chairperson of LNTH Board and CEO of King Pharmaceuticals. | View Report → |
Amanda Morgan Executive | Chief Commercial Officer (CCO) | None | Joined LNTH in 2022; promoted to CCO in 2024; previously Chief Revenue and Customer Officer at Acadia Pharmaceuticals. | |
Daniel M. Niedzwiecki Executive | Chief Administrative Officer, General Counsel, and Corporate Secretary | None | Over 20 years of legal and business experience; joined LNTH in 2013 and oversees legal, compliance, HR, and communications. | |
Dr. Jean-Claude Provost Executive | Chief Science Officer (CSO) | Board Member of the Centre for Probe Development and Commercialization (CPDC). | Over 30 years of experience in radiopharmaceuticals; transitioned from CMO to CSO in 2024. | |
Etienne Montagut Executive | Chief Business Officer (CBO) | None | Joined LNTH in 2018; led key collaborations, including the POINT Biopharma partnership. | |
Paul M. Blanchfield Executive | President | None | Former Chief Commercial Officer and Chief Operating Officer at LNTH; led the successful launch of PYLARIFY. | |
Robert J. Marshall Jr. Executive | Chief Financial Officer (CFO) | None | Over 30 years of finance experience; previously held senior roles at Zimmer Biomet Holdings, Inc.. | |
Dr. James H. Thrall Board | Director | None | Distinguished Juan M. Taveras Professor of Radiology at Harvard Medical School; former Chair of Radiology at Massachusetts General Hospital. | |
G\u00e9rard Ber Board | Director | Board Member at Y-mAbs Therapeutics, Inc. and Evergreen Theragnostics. | Over 30 years of experience in molecular nuclear medicine; expertise in product development and commercialization. | |
Gary J. Pruden Board | Director | Board Member at Motus GI Holdings, Ossio Inc., Avisi Technologies, and Olympus Corporation. | Over 30 years of experience in the healthcare industry; former senior executive at Johnson & Johnson. | |
Heinz M\u00e4usli Board | Director | Board Member at Inventiva SA. | Over 15 years of experience in molecular nuclear medicine; financial and legal expertise. | |
Julie Eastland Board | Director | Independent Director at Dynavax Technologies and Veana Therapeutics. | Former CEO of Harpoon Therapeutics; extensive financial and operational leadership in biotech. | |
Julie McHugh Board | Lead Independent Director | Chair of the Board at Ironwood Pharmaceuticals; Board Member at Evelo Biosciences and New Xellia Group A/S. | Former COO of Endo Health Solutions; extensive experience in pharmaceutical and biotech industries. | |
Mary Anne Heino Board | Chair of the Board of Directors | Executive Committee of the Massachusetts Business Roundtable; Board of MassMEDIC. | Former CEO of LNTH (2015–2024); led LNTH's growth in radiopharmaceuticals and diagnostics. | |
Minnie Baylor-Henry Board | Director | Independent Director at Apyx Medical, Paratek Pharmaceuticals, and scPharmaceuticals. | Former Worldwide VP for Regulatory Affairs at Johnson & Johnson; extensive regulatory and compliance expertise. | |
Samuel R. Leno Board | Director | Board Member at GCM Manufacturing. | Over 40 years of financial and operational leadership experience; Vietnam veteran. |
- Given the net price compression from strategic partnerships affecting PYLARIFY's Q3 revenues, how do you anticipate this price pressure impacting revenue growth in 2025, and do you expect similar pricing dynamics to continue?
- With the SPLASH study's OS results confounded by high patient crossover to PNT2002, what specific strategies are you considering to address this issue with the FDA, and how might this affect the regulatory timeline for PNT2002's approval?
- Considering the potential for CMS pricing adjustments and increasing competition for PYLARIFY, how confident are you in maintaining its blockbuster status in 2025 and sustaining long-term growth amidst net price compression from strategic partnerships?
- Can you elaborate on how MK-6240 and NAV-4694 will differentiate themselves from existing imaging agents and emerging blood tests in Alzheimer's diagnostics, and what substantiates your confidence in achieving the projected $1.5 billion market size by the end of the decade?
- With rising costs in materials, freight, and overhead partially offsetting gross margin improvements, what measures are you implementing to manage these costs and sustain or improve gross margins amid potential pricing pressures and increased R&D investments?
Research analysts who have asked questions during Lantheus Holdings earnings calls.
Anthony Petrone
Mizuho Group
4 questions for LNTH
Justin Walsh
Jones Trading
4 questions for LNTH
Richard Newitter
Truist Securities
4 questions for LNTH
Yuan Zhi
B. Riley Financial, Inc.
4 questions for LNTH
David Turkaly
Citizens JMP
3 questions for LNTH
John Vandermosten
Zacks Small Cap Research
3 questions for LNTH
Lawrence Solow
CJS Securities, Inc.
3 questions for LNTH
Matthew Taylor
Jefferies
3 questions for LNTH
Roanna Clarissa Ruiz
Leerink Partners
3 questions for LNTH
Tsan-Yu Hsieh
William Blair & Company
3 questions for LNTH
Brian Kemp Dolliver
Brookline Capital Markets, LLC
2 questions for LNTH
Kemp Dolliver
Brookline Capital Markets
2 questions for LNTH
Tara Bancroft
TD Cowen
2 questions for LNTH
Andy Hsieh
William Blair & Company
1 question for LNTH
Ed Wild
Redburn Atlantic
1 question for LNTH
Frances Dovell
TD Cowen
1 question for LNTH
Kyuwon Choi
Goldman Sachs
1 question for LNTH
Larry Solow
CJS Securities
1 question for LNTH
Matt Taylor
Jefferies & Company Inc.
1 question for LNTH
Mazahir Alimohamed
Leerink Partners
1 question for LNTH
Paul Choi
Goldman Sachs
1 question for LNTH
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
Evergreen Theragnostics | 2025 | Lantheus acquired Evergreen Theragnostics with an upfront cash payment of $250 million and milestone payments up to $752.5 million, enhancing manufacturing capabilities and expanding its oncology pipeline with OCTEVY for neuroendocrine tumors. |
Life Molecular Imaging | 2025 | The acquisition of Life Molecular Imaging involved a $350 million upfront cash payment, up to $400 million in contingent earn-outs, and additional liabilities, strategically expanding the AD radiodiagnostic franchise through Neuraceq and bolstering global commercial capabilities. |
Meilleur Acquisition | 2024 | The Meilleur acquisition was an asset purchase for NAV-4694, a Phase 3 F-18 PET imaging agent for Alzheimer’s disease, with an upfront payment of approximately $32.9 million plus additional milestone payments, aligning with the company’s diagnostic advancement goals. |
Radiopharm Theranostics Limited Agreement | 2024 | This limited agreement secured exclusive global rights to two preclinical assets—a TROP2-targeted nanobody and an LRRC15-targeted monoclonal antibody (DUNP19)—for an upfront payment of $2.0 million plus milestone and potential equity investment components, broadening the oncology portfolio. |
Cerveau Technologies, Inc. | 2023 | The acquisition of Cerveau Technologies, Inc. for its MK-6240 asset involved a $35.0 million upfront payment, additional technology transfer fees, and significant milestone and sales payments to bolster Lantheus’s diagnostic imaging portfolio for Alzheimer’s disease. |
PNT-2002 License Agreement | 2022 | The PNT-2002 License Agreement with POINT Biopharma granted Lantheus Two exclusive worldwide rights (with limited exceptions) for co-developing a prostate-specific radiopharmaceutical, involving a $250 million upfront payment and up to $1.28 billion in sales milestones plus regulatory payments. |
PNT-2003 License Agreement | 2022 | The PNT-2003 License Agreement entered via Lantheus Three provided rights to co-develop a somatostatin receptor-targeted radioligand therapy for neuroendocrine tumors, with a $10 million upfront payment, additional milestone and sales payments, and a 15% royalty on net sales. |
Recent press releases and 8-K filings for LNTH.
- Faruqi & Faruqi, LLP is investigating Lantheus Holdings (LNTH) for a federal securities class action due to alleged misleading statements concerning Pylarify's competitive position.
- The complaint indicates investors suffered losses between February 26, 2025, and August 5, 2025, due to artificially inflated stock prices.
- On August 6, 2025, Lantheus' stock price declined by 28.8% to $51.87 per share, following disappointing Q1 results and significantly reduced fiscal year 2025 growth projections for Pylarify.
- The deadline for investors to seek the role of lead plaintiff in the class action is November 10, 2025.
- Faruqi & Faruqi, LLP is investigating potential securities claims against Lantheus Holdings, Inc. (LNTH) due to alleged misleading statements concerning the competitive position, pricing, revenue, and growth potential of its product, Pylarify.
- Investors who suffered losses in Lantheus between February 26, 2025, and August 5, 2025, are encouraged to discuss their legal rights.
- The investigation follows Lantheus reporting first-quarter results below market expectations on May 7, 2025, with Pylarify's performance falling short.
- On August 6, 2025, Lantheus announced disappointing results and significantly reduced growth expectations for Pylarify, which had fallen 8.3% year-over-year, and slashed fiscal year 2025 growth projections, attributing the losses to ongoing competition impacting Pylarify’s pricing dynamics.
- Following these revelations, Lantheus' stock price declined by approximately 28.8% on August 6, 2025, falling from $72.83 per share on August 5, 2025, to $51.87 per share. The deadline for investors to seek the role of lead plaintiff is November 10, 2025.
- Faruqi & Faruqi, LLP is investigating Lantheus Holdings, Inc. (LNTH) for potential federal securities class action claims.
- The investigation concerns alleged misleading statements regarding Pylarify's competitive position, pricing, revenue, and overall growth potential.
- Investors who purchased or acquired securities between February 26, 2025, and August 5, 2025, are encouraged to contact the firm.
- Lantheus's stock price declined by approximately 28.8% on August 6, 2025, from $72.83 to $51.87 per share, following disappointing Q1 and Q2 2025 results and significantly reduced growth expectations for Pylarify.
- The deadline for investors to seek the role of lead plaintiff is November 10, 2025.
- Lantheus Holdings, Inc. (LNTH) is subject to a class action lawsuit for investors who purchased securities between February 26, 2025, and August 5, 2025.
- The lawsuit alleges that the company and its executives misled investors about the growth and pricing strength of its key prostate cancer imaging product, Pylarify, by concealing that price hikes and competitive pressures were eroding its market position.
- Lantheus's stock dropped over 23% and 28% in May and August 2025, respectively, following quarterly results that revealed sharp sales declines, reduced guidance, and intensifying competition.
- Investors have until November 10, 2025, to file a lead plaintiff motion.
- Faruqi & Faruqi, LLP is investigating Lantheus Holdings, Inc. for a federal securities class action concerning alleged misleading statements about Pylarify's competitive position, pricing, revenue, and growth potential.
- The class action covers investors who suffered losses between February 26, 2025, and August 5, 2025.
- The deadline for investors to seek the role of lead plaintiff is November 10, 2025.
- On August 6, 2025, Lantheus announced disappointing results and significantly reduced growth expectations for Pylarify, attributing losses to ongoing competition.
- Following this announcement, Lantheus's stock price declined approximately 28.8%, falling from $72.83 per share on August 5, 2025, to $51.87 per share on August 6, 2025.
- Pomerantz LLP has filed a class action lawsuit against Lantheus Holdings, Inc. (LNTH), alleging securities fraud or unlawful business practices.
- The lawsuit highlights two significant stock price declines in 2025 following disappointing financial results and reduced full-year projections.
- On May 7, 2025, Lantheus's stock fell 23.23% after Q1 2025 results missed expectations and its radiopharmaceutical oncology product Pylarify experienced a year-over-year sales decrease.
- On August 6, 2025, the stock dropped 28.58% after Q2 2025 results missed EPS and revenue expectations, with Pylarify sales falling 8.3% year-over-year due to ongoing competition and pricing dynamics.
- Investors have until November 10, 2025, to ask the Court to appoint them as Lead Plaintiff.
- Faruqi & Faruqi, LLP is investigating Lantheus Holdings, Inc. (LNTH) and a federal securities class action has been filed against the company.
- The lawsuit alleges that Lantheus provided misleading statements concerning the competitive position, pricing, revenue, and growth potential of its product, Pylarify.
- Lantheus' stock price declined by approximately 28.8% on August 6, 2025, falling from $72.83 to $51.87 per share, after announcing disappointing Q1 results and significantly reduced fiscal year 2025 growth expectations for Pylarify.
- Investors who suffered losses exceeding $75,000 between February 26, 2025, and August 5, 2025, are encouraged to contact the firm, with a deadline to seek lead plaintiff status by November 10, 2025.
- The Portnoy Law Firm has announced a class action lawsuit against Lantheus Holdings, Inc. (NASDAQ: LNTH) on behalf of investors who purchased securities between February 26, 2025, and August 5, 2025.
- Investors have until November 10, 2025, to file a lead plaintiff motion.
- The complaint alleges that Lantheus executives misled investors regarding the growth and pricing strength of Pylarify, its key prostate cancer imaging product.
- The lawsuit claims that the company concealed that price hikes and competitive pressures were eroding Pylarify's market position, leading to stock drops of over 23% and 28% in May and August 2025, respectively, after quarterly results revealed sharp sales declines, reduced guidance, and intensifying competition.
- Pomerantz LLP is investigating Lantheus Holdings, Inc. for potential securities fraud or other unlawful business practices.
- The investigation follows Lantheus's announcement of disappointing Q2 2025 results, with consolidated net revenue of $378 million and Radiopharmaceutical oncology PYLARIFY sales of $250.6 million, both lower than previously expected.
- Lantheus also lowered its full-year 2025 revenue guidance from $1.550 billion - $1.585 billion to $1.475 billion - $1.51 billion and its adjusted fully diluted EPS guidance from $6.60 - $6.70 per share to $5.50 - $5.70 per share.
- Following this news, Lantheus's stock price fell $20.76 per share, or 28.58%, to close at $51.87 per share on August 6, 2025.
- Polarify generated $1.58 billion in sales in 2024 with expected 15–17% TAM growth in 2025.
- Definity delivered $80 million in Q1 2025 and sits at
50% US TAM penetration ($350 million), targeting mid-single-digit annual growth. - Lantheus is set to close its acquisitions of Evergreen’s Octavvy diagnostics and Life Molecular Imaging, while divesting its spec business (~$120 million in revenue).
- Key pipeline catalysts include MK-6240 (tau) NDA filing in Q3 2025; NAV (beta-amyloid) filing in 2026; Octavvy and LNT-203 launches targeted mid-2026; plus early assets GRPR and LLRC15.
- Management expects to achieve double-digit organic revenue growth in 2026 driven by stabilized Polarify pricing, normalized Definity growth, NeuroSeq launch, and new mid-term product rollouts.